title: [Contribution of novel anticoagulants fondaparinux and dabigatran to venous thromboembolism prevention].
abstract: The data that episodes and sequels of venous thromboembolism (VTE) are recorded in a significant percentage of patients receiving standard anticoagulants as VTE prophylaxis (unfractionated, low-molecular-weight heparin and vitamin K inhibitors) as well as the fact that these drugs have significant limitations and that they may cause serious side-effects in some patients indicate the need for the introduction of new anticoagulant drugs. Fondaparinux, a selective inhibitor of Factor Xa, administered following major orthopedic surgeries having a high risk for the development of VTE, is more efficient than enoxaparin sodium used in European and North-American approved doses. The increased incidence of major bleeding (excluding fatal) due to fondaparinux could be perhaps lowered by dosage reduction in patients with a mildly decreased creatinine clearance. Dabigatran, a peroral direct thrombin inhibitor, administered for VIE prophylaxis in elective hip and knee surgery, showed in to date studies the efficacv comparable (if dabiqatran is given in both dosage regimes of 150 mg and 220 mg daily) or superior (if dabigatran is given at a dose of 220 mg daily) to enoxaparin administered in European-approved doses, while North American-approved doses of enoxaparin were superior than dabigatran in VTE reduction. No significant differences in bleeding rates were determined in any of the study groups. We consider that the introduction of new anticoagulants, including fondaparinux and dabigatran, will contribute to the establishment of a better safety profile and efficacy, and will also enable adequate therapy individualization for each patient depending on his/hers clinical characteristics. The introduction of novel peroral anticoagulants will, inter alia, significantly contribute to improvement in the quality of life, release the patient from numerous limitations in nutrition, interreaction, frequent laboratory monitoring, and also significantly improve therapeutic predictability.
authors.forename: Nebojša
authors.initials: N
authors.lastname: Antonijević
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kanjuh
authors.forename: Ivana
authors.initials: I
authors.lastname: Živković
authors.forename: Ljubica
authors.initials: L
authors.lastname: Jovanović
authors.forename: Miodrag
authors.initials: M
authors.lastname: Vukčević
authors.forename: Milan
authors.initials: M
authors.lastname: Apostolović
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D000069604:Dabigatran; D000077425:Fondaparinux; D006801:Humans; D019637:Orthopedic Procedures; D011134:Polysaccharides / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000517:prevention & control*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D011134:Polysaccharides; D015091:beta-Alanine; D000069604:Dabigatran; D000077425:Fondaparinux